INDSWFTLTD2024-04-012024-06-30 INDSWFTLTD2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member INDSWFTLTD2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524652 INDSWFTLTD NOTLISTED Ind-Swift Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-01 INR Lakhs First quarter 17:30:00 18:40:00 2024-08-13 2024-08-13 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Standalone 1138508000.00 399312000.00 1537820000.00 555483000.00 121110000.00 -39535000.00 199302000.00 95432000.00 53690000.00 269948000.00 1255430000.00 282390000.00 0.00 282390000.00 0.00 0.00 0.00 0.00 282390000.00 0.00 0.00 0.00 0.00 282390000.00 0.00 282390000.00 0.00 0.00 108329000.00 2 5.21 5.21 0.00 0.00 5.21 5.21 Notes:- 1 The above financial results have been prepared in accordance with IND-AS prescribed under section 133 of Companies Act,2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015. 2 During the Quarter, the Company has completed the transfer of Unit No III to ANG Lifescience Ltd and profit on Sale of the same of Rs. 2872.81 lacs is reflected under the head 'Other Income' in the above Quarterly Results. 3 The Company has announced the merger of the Company with Ind Swift Laboratories Ltd and the application seeking no objection of the Stock Exchange has been filed under regulation 37 of SEBI (LODR) Regulation 2015 with the NSE and BSE and same are pending for approval. 4 Provision for Current and Deferred Tax will be made at the year end. 5 The Company is exclusively in Pharmaceutical business. 6 Previous period/ year figures have been re-grouped/Re-arranged where ever necessary. 7 The above Standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 13th August 2024. Other Expenses 269948000.00 0.00 0.00